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Background: This secondary analysis aimed to identify predictors of low (<6 oocytes retrieved) and high ovarian
response (>18 oocytes retrieved) in IVF patients undergoing controlled ovarian stimulation with corifollitropin alfa in
a gonadotropin-releasing hormone (GnRH) antagonist protocol.
Methods: Statistical model building for high and low ovarian response was based on the 150 μg corifollitropin alfa
treatment group of the Pursue trial in infertile women aged 35–42 years (n = 694).
Results: Multivariable logistic regression models were constructed in a stepwise fashion (P <0.05 for entry). 14.1 %
of subjects were high ovarian responders and 23.2 % were low ovarian responders. The regression model for high
ovarian response included four independent predictors: higher anti-Müllerian hormone (AMH) and antral follicle
count (AFC) increased the risk, and higher follicle-stimulating hormone (FSH) levels and advancing age decreased
the risk of high ovarian response. The regression model for low ovarian response also included four independent
predictors: advancing age increased the risk, and higher AMH, higher AFC and longer menstrual cycle length
decreased the risk of low ovarian response.
Conclusions: AMH, AFC and age predicted both high and low ovarian responses, FSH predicted high ovarian
response, and menstrual cycle length predicted low ovarian response in a corifollitropin alfa/GnRH antagonist
protocol.
Trial registration number: NCT01144416, Protocol P06029
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In assisted reproductive technology, both very low and
very high ovarian responses to ovarian stimulation have
been associated with increased cancellation rates and
compromised pregnancy and live birth rates [1, 2]. A
high ovarian response also increases the risk for develop-
ment of ovarian hyperstimulation syndrome (OHSS) [3].
Early identification of potential low and high responders
is relevant to enable individualization of the ovarian
stimulation treatment regimen [4].
The majority of studies on predictors of ovarian response
have analyzed patients treated with recombinant (r) follicle-* Correspondence: OehninSC@EVMS.edu
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hormone (GnRH) agonist protocols. Systematic reviews
have identified anti-Müllerian hormone (AMH), antral fol-
licle count (AFC) and basal FSH as predictors of low ovar-
ian response and AMH and AFC as predictors of high
ovarian response in these protocols [5, 6], although
the independence of these markers has not always
been tested. AFC, basal FSH, luteinizing hormone
(LH) and AMH have been identified as common
prognostic factors for low or high ovarian response in
rFSH GnRH antagonist protocols [7, 8].
Corifollitropin alfa is a novel recombinant gonado-
tropin, a single dose of which is capable of initiating and
sustaining multifollicular growth during the first 7 days
of ovarian stimulation as a replacement for 7 daily injec-
tions with rFSH. The treatment regimen retains theticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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day 7 [9]. A retrospective cohort study in young women
treated with corifollitropin alfa in a GnRH antagonist
protocol has shown that AMH and AFC are the best
predictors for low and excessive response [10].
More women are delaying pregnancy, resulting in an
increased number of women over the age of 35 years
seeking infertility care [11]. The Pursue trial showed that
in women aged 35–42 years, a single injection of 150 μg
corifollitropin alfa was noninferior to daily injections of
300 IU rFSH for the first 7 days of ovarian stimulation
prior to in vitro fertilization (IVF) or intracytoplasmic
sperm injection (ICSI) in terms of the vital pregnancy
rate and was equally well tolerated with a low incidence
of OHSS [12].
The objective of the current study was to identify pre-
dictors of low and high ovarian response in IVF/ICSI
patients aged 35 to 42 years undergoing ovarian stimula-
tion with corifollitropin alfa in a GnRH antagonist
protocol, using data from the corifollitropin alfa arm of
the Pursue trial.
Materials and methods
This was a secondary analysis of data collected in the
Pursue trial (N = 1390) (Trial registration number:
NCT01144416; Protocol P06029), a double-blind, ran-
domized controlled trial of corifollitropin alfa versus
daily injections of rFSH [12]. The trial was conducted in
accordance with principles of Good Clinical Practice and
was approved by the appropriate institutional review
boards and regulatory agencies (Chesapeake IRB,
Columbia (http://www.chesapeakeirb.com/)). Written in-
formed consent was provided by all subjects. Infertile
women aged 35–42 years with a body weight of ≥50 kg
and body mass index (BMI) ≥18 and ≤32 kg/m2 received
either a single injection of 150 μg corifollitropin alfa or
daily injections of 300 IU rFSH for the first 7 days of
stimulation, followed by ≤300 IU/d rFSH starting on
stimulation day 8, if needed. GnRH antagonist treat-
ment, 0.25 mg/d ganirelix, was started on day 5 until
final oocyte maturation with 250 μg recombinant hu-
man chorionic gonadotropin [12]. Patients were ex-
cluded if they had a history of, or current, polycystic
ovary syndrome.
Validated immunoassays were performed at a cen-
tral laboratory on frozen serum samples to assess
FSH, LH, estradiol (E2) and progesterone (P) concen-
trations as previously described [13]. Assessment of
AMH was carried out using the validated Active
AMH Gen II ELISA pre-mix assay from Beckman
Coulter, Inc. (Brea, California, USA).
Limits of high and low ovarian response used in
the current analyses were set at >18 oocytes retrieved
and <6 oocytes retrieved, respectively.Statistical methods
Initially, separate logistic regression models were con-
structed for high ovarian response (>18 oocytes retrieved
or cycle canceled by the investigator because of too high
response) and low ovarian response (<6 oocytes re-
trieved or cycle canceled due to insufficient response).
Age was included as the first variable in both models.
Other candidate prognostic factors were age at menar-
che (years), average menstrual cycle length (days), dur-
ation of infertility (years), BMI (kg/m2), AFC and serum
levels of FSH (IU/L), LH (IU/L), E2 (pmol/L), P (nmol/L)
and AMH (ng/mL) on day 1 of stimulation. For each
candidate predictor, the association with high and low
ovarian response was assessed using a χ2 test (the score
test in a logistic regression model including only that
predictor).
Multivariate logistic regression models were constructed
in a stepwise fashion (P < 0.05 for entry and P > 0.05 for
removal). Ten subjects with missing values (1.5 %) were
excluded from model building, but were included in the
estimation of the final model with missing covariate values
imputed. For both outcomes the receiver operating char-
acteristic (ROC) curve was plotted and the area under the
curve (AUC, c-statistic) was calculated. This was done for
the final model as well as for the intermediate models.
These values were denoted ‘apparent’ AUCs. Optimism-
corrected values were calculated using leave-one-out
cross-validation (where the regression coefficients were
re-estimated with each subject left out and then combined
with the subject’s covariate values in order to mimic the
prediction of the outcome for each subject). The ‘optimal’
point on the ROC curve providing the best trade-off be-
tween sensitivity and specificity and the associated ‘op-
timal’ probability cutoff were identified. Sensitivity,
specificity, positive predictive value and negative predict-
ive value at the optimal cutoff were calculated.
Additionally, a combined model was constructed to
predict both high and low ovarian by including the pre-
dictors that appeared in both models for the separate
endpoints. The impact of leaving out prognostic factors
that appeared in only one of the models was investi-
gated. In the combined model, the regression coefficient
of a given factor was allowed to differ between the out-
comes of high and low ovarian response (i.e., propor-
tional odds was not assumed).
External model validation was not possible as Pursue
was the only study with corifollitropin alfa for which
AMH measurements were available. Instead, models
were internally validated by bootstrapping [14]. A total
of 500 samples from 686 were drawn with replacement
from the data set analyzed and for each sample, a logis-
tic regression model was fitted for high, and separately,
for low ovarian response using the stepwise approach
described above. Each model was validated using the
Oehninger et al. Reproductive Biology and Endocrinology  (2015) 13:117 Page 3 of 7subjects not included in the bootstrap sample (on average,
36.8 %) [15]. Validation focused on discrimination—the
ability of the model to distinguish between subjects with
and without the event of interest, and calibration—the
correspondence between the predicted event probabilities
and observed proportions. Discrimination was measured
by the AUC (or c-statistic) and calibration was measured
by the calibration slope. Both quantities were obtained by
fitting a logistic regression model in the validation sample
with a single covariate for the so-called linear predictor, a
combination of covariate values (from subjects in the val-
idation sample) and regression coefficients (from the
model constructed in the bootstrap sample). The calibra-
tion slope is the regression coefficient of the linear pre-
dictor, which should be close to unity. If the calibration
slope is markedly less than one, this suggests that predic-
tions should be ‘shrunken’ toward the mean when applied
to future patients. The distribution of AUCs and calibra-
tion slopes was summarized over the 500 validation
samples.
Finally, we compared our models with those developed
by Polyzos et al. for excessive (>20 oocytes retrieved)
and poor ovarian response (<3 oocytes retrieved). It
should be noted, however, that the Polyzos et al. models
were based on younger women from a single European
center [10].
All analyses were performed using SAS PC version 9.3
(SAS Institute Inc., Cary, NC, USA).
Results
In this study population, 14.1 % of women were high




(n = 686) (n = 15
Age at baseline, y, mean (SD) 38.0 (2.2) 38
Age at menarche, y, mean (SD) 12.9 (1.5) 12
Average menstrual cycle length, days, mean (SD) 28.2 (1.7) 27
Duration of infertility, y, mean (SD) 2.8 (2.8) 2
BMI at baseline, kg/m2, mean (SD) 25.1 (3.6) 25
AFC at day 1 of stimulation, n, mean (SD) 10.8 (4.0) 7
(n = 679) (n = 15
FSH at day 1 of stimulation, IU/L, median 6.9 8
LH at day 1 of stimulation, IU/L, median 4.6 4
Estradiol at day 1 of stimulation, pmol/L, median 140.6 140
Progesterone at day 1 of stimulation, nmol/L, median 1.9 1
AMH at day 1 of stimulation, ng/mL, median 1.5 0
Note: 8 subjects who did not have oocyte retrieval (for reasons other than too low
from the analysis
SD standard deviation, BMI body mass index, AFC antral follicle count, FSH follicle-stwere low ovarian responders (<6 oocytes retrieved). De-
scriptive statistics of potential predictors for ovarian re-
sponse are shown in Table 1. These analyses showed
that age at baseline, menstrual cycle length, AFC, FSH
and AMH had a strong (P < 0.001) association with both
high and low ovarian response.
High ovarian response
The logistic regression model for high ovarian response
included four independent predictors (Table 2). Higher
AMH concentrations and AFCs increased the risk for
high ovarian response and higher FSH levels and advan-
cing age decreased the risk. The apparent AUC of the
ROC curve for the complete model predicting high ovar-
ian response was 0.888 (Fig. 1). Correcting for the opti-
mism associated with measuring the performance of the
model in the same data set in which the model was con-
structed, the AUC was 0.880 (Table 2).
Table 2 and Fig. 1 also show that high ovarian response
cannot be predicted by age alone (apparent AUC= 0.613).
Adding AMH strongly increased the ability of the model
to separate patients with high ovarian response from those
without high ovarian response (AUC= 0.864). Further in-
clusion of AFC and FSH also increased the performance
of the model, but to a lesser extent (AUC= 0.888). The
sensitivity and specificity of the final model were 84 % and
80 %, respectively (Table 3). The regression equation for
the final model is given in Table 3 (first row). The
equation can be used to calculate the probability for
high ovarian response for any patient, given her age,
AMH, AFC and FSH. For a 38-year-old patient with










9) (n = 430) (n = 97) (P-value) (P-value)
.6 (2.2) 37.9 (2.1) 37.3 (2.1) <0.001 <0.001
.6 (1.4) 12.9 (1.5) 13.1 (1.6) 0.097 0.026
.5 (1.5) 28.3 (1.7) 28.7 (1.7) <0.001 <0.001
.5 (2.3) 2.9 (2.8) 3.2 (3.2) 0.169 0.100
.1 (3.6) 25.1 (3.7) 25.0 (3.4) 0.705 0.893
.8 (3.1) 11.2 (3.6) 14.5 (3.4) <0.001 <0.001
7) (n = 426) (n = 96)
.2 6.9 6.1 <0.001 <0.001
.2 4.7 4.7 0.555 0.089
.2 141.5 138.4 0.163 0.981
.9 1.9 2.0 0.984 0.849
.5 1.6 3.2 <0.001 <0.001
or too high ovarian response according to the investigator) were excluded
imulating hormone, LH luteinizing hormone, AMH anti-Müllerian hormone
Table 2 Logistic regression model for high ovarian response
(>18 oocytes)
Covariate OR 95 % CI P-value AUCa AUCb
Age (years) 0.88 0.78 1.00 0.0590 0.613 0.545
AMH (ng/mL) 1.93 1.58 2.36 <0.0001 0.864 0.858
AFC (count) 1.20 1.11 1.29 <0.0001 0.882 0.876
FSH (IU/mL) 0.78 0.65 0.93 0.0055 0.888 0.880
All odds ratios (OR) are per unit increase
CI confidence interval, AUC area under the curve, AMH anti-Müllerian hormone,
AFC antral follicle count, FSH follicle-stimulating hormone
aApparent
bOptimism-corrected
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high ovarian response is 0.064, or 6.4 %. For another
38-year-old patient with AMH = 0.8 ng/mL, AFC = 8
and FSH = 8.5 IU/L, the LP = −4.136 and the probabil-
ity for high ovarian response is 0.016, or 1.6 %.
Low ovarian response
The multivariable regression model for low ovarian re-
sponse also included four independent predictors
(Table 4). Advancing age increased the risk for low ovar-
ian response and higher AMH, higher AFC and longer
menstrual cycle length decreased the risk. The apparent
AUC of the ROC curve for the complete model predict-
ing low ovarian response was 0.886 (Fig. 2). The
optimism-corrected AUC was 0.877 (Table 4).
Table 4 and Fig. 2 again show that low ovarian re-
sponse cannot be predicted by age alone (apparent
AUC = 0.605). Adding AMH strongly increased the dis-
criminative ability of the model (AUC = 0.871), whereas
further inclusion of AFC and menstrual cycle length alsoFig. 1 Receiver operating characteristic curves for models for high ovarian re
hormone; AFC: antral follicle count; FSH: follicle-stimulating hormoneincreased the performance of the model (AUC= 0.886).
The sensitivity and specificity of the final model were
77 % and 87 %, respectively (Table 3). The regression
equation for the final model is given in Table 3 (second
row). For a 38-year-old patient with AMH= 1.8 ng/mL,
AFC = 11 and a menstrual cycle length of 28 days, the lin-
ear predictor LP = −2.548 and the probability for low ovar-
ian response is 0.073, or 7.3 %. For the 38-year-old patient
with AMH= 0.8 ng/L, AFC = 8 and FSH= 8.5 IU/L, the
LP = −0.359 and the probability for low ovarian response
is 0.411, or 41.1 %.
Combined model
The regression models for high and low ovarian re-
sponse had three predictors in common: age, AMH and
AFC. The added value of FSH in the model for high
ovarian response, although statistically significant, was
not overwhelming. The same is true for menstrual cycle
length in the model for low ovarian response. Without
these factors, the AUC would decrease by only 0.006
and 0.004 for high and low ovarian response, respect-
ively. Although age could also be dropped from the
model without losing much predictive power, this factor
was kept in the model as it is readily available. It should
be noted that predicting high and low ovarian response
based on the combined regression model should be
based on different regression equations (Table 3, third
and fourth rows). For the 38-year-old patient with
AMH= 1.8 ng/mL and AFC = 11, the linear predictors for
high and low ovarian response are −2.504 and −2.550,
respectively and the associated probabilities are 7.6 % and
7.2 %, respectively (the estimates based on previous
models were 7.3 % and 7.3 %, respectively). The remainingsponse (>18 oocytes). AUC: area under the curve; AMH: anti-Müllerian
Table 3 Test characteristics and equations for models for high and low ovarian response
Predictive value
Model Cutoff Sensitivity Specificity Positive Negative
High ovarian responsea 0.15 0.84 0.80 0.41 0.97
Low ovarian responseb 0.37 0.77 0.87 0.64 0.93
Combined high ovarian responsec 0.13 0.87 0.78 0.39 0.97
Combined low ovarian responsed 0.36 0.78 0.86 0.62 0.93
Model-based probability P ¼ eLP1þeLP where LP is the linear predictor
aLP = 0.6953 – 0.1232 × age [years] + 0.6596 × AMH [ng/mL] + 0.1829 × AFC [count] – 0.2517 × FSH [IU/mL]
bLP = 5.1380 + 0.0961 × age [years] – 1.6821 × AMH [ng/mL] – 0.1690 × AFC [count] – 0.2304 × CLn [days]
cLP = −1.1213 – 0.1258 × age [years] + 0.7010 × AMH [ng/mL] + 0.1942 × AFC [count]
dLP = −0.7701 + 0.0828 × age [years] – 1.7373 × AMH [ng/mL] – 0.1635 × AFC [count]
If the model-based predicted probability is above the cutoff, a patient would be classified as a potential high (respectively, low) responder
AMH anti-Müllerian hormone, AFC antral follicle count, CLn cycle length, FSH follicle-stimulating hormone
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tween six and 18 oocytes.
Interpretation and application of the model would be
simpler if age, AMH and AFC were classified as ‘high’ or
‘low,’ for example, by using a threshold that optimizes
sensitivity and specificity for each single factor. For high
ovarian response, these thresholds are age ≤37 years,
AMH ≥2.24 ng/mL and AFC ≥13 (details not shown).
For low ovarian response, the values are age ≥39 years,
AMH ≤1.03 ng/mL and AFC ≤9. However, it is well
known that dichotomization of continuous covariates
leads to loss of information. Indeed, the AUC of the sim-
pler model for high ovarian response drops to 0.867
(from 0.882) and the AUC of the simpler model for high
ovarian response drops to 0.841 (also from 0.882). For
this reason, the simpler models were not pursued
further.
Model validation
The bootstrap validation of the model for high ovarian
response (including variable selection) resulted in a me-
dian AUC of 0.895 in the validation samples (2.5 and
97.5 percentage points: 0.862 and 0.923). The median
calibration slope was 0.990 (0.964–1.004). The validation
of the model for low ovarian response based on the
same 500 bootstrap samples resulted in a median AUC
of 0.890 (0.857–0.917) and a median calibration slope ofTable 4 Logistic regression model for low ovarian response
(<6 oocytes)
Covariate OR 95 % CI P-value AUCa AUCb
Age (years) 1.10 0.99 1.22 0.0711 0.605 0.553
AMH (ng/mL) 0.19 0.12 0.28 <0.0001 0.871 0.867
AFC (count) 0.85 0.78 0.91 <0.0001 0.882 0.877
Menstrual cycle length (days) 0.79 0.69 0.92 0.0017 0.886 0.877
Odds ratios are per unit increase
CI, confidence interval, AUC area under the curve, AMH anti-Müllerian hormone,
AFC antral follicle count
aApparent
bOptimism-corrected0.937 (0.557–1.461). These results suggested good dis-
crimination and calibration for high and low ovarian
response.
Comparison with the model of Polyzos et al.
Our findings agree with those of Polyzos et al. [10] in
that AMH and AFC are important predictors of ovar-
ian response. Polyzos et al. developed models for ex-
cessive ovarian response (>20 oocytes retrieved) and
poor ovarian response (<3 oocytes retrieved) based on
AMH and AFC. The linear predictor for excessive
ovarian response based on our data would be LP =
– 7.287 + 0.664 × AMH + 0.260 × AFC (details not
shown), rather similar to the regression equation of Polyzos
et al. (z = – 6.782 + 0.557 × AMH + 0.172 × AFC).
Our linear predictor for poor ovarian response,
LP = 0.964 – 2.710 × AMH – 0.167 × AFC, however,
is different from their regression equation
(z = 2.161 – 0.991 × AMH – 0.171 × AFC). The
main reason is that the percentage of poor responders
in our data set is markedly lower than reported by
Polyzos et al. (6.7 % versus 34.3 %). This difference
could not be accounted for by possibly different
values of AMH and AFC in our population. The per-
centages of excessive response were similar (9.5 %
versus 8.6 %). Using the linear predictors of Polyzos
et al. in our data resulted in calibration slopes of 1.31
and 1.72 for excessive and poor response, respectively.
These were statistically significantly different from
one (P = 0.032 and P = 0.0032, respectively), suggesting
that these predictors should not be used for older
women. Predictive models inevitably reflect the data
set from which they are derived, which is why we
made the validation effort.
Discussion
In the population of women in the Pursue trial aged 35–
42 years old undergoing ovarian stimulation with corifolli-
tropin alfa in a GnRH antagonist protocol, the predictive
factors for high ovarian stimulation were age, AFC, basal
Fig. 2 Receiver operating characteristic curves for models for low ovarian response (<6 oocytes). AUC: area under the curve; AMH: anti-Müllerian
hormone; AFC: antral follicle count
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GnRH agonist and antagonist protocols [5–8]. In the older
patient population in the Pursue trial [12], increased men-
strual cycle length was identified as a factor that decreased
the risk of low ovarian response. Women with a history of
polycystic ovary syndrome were excluded. Compared with
younger women (18–36 years old) undergoing ovarian
stimulation with rFSH in a GnRH antagonist protocol, in
the current analyses, increased LH and BMI [16] were not
identified as predictors of high ovarian response [8].
In this study, AMH concentrations were measured on
frozen serum samples using the Active AMH Gen II
ELISA pre-mix assay. For stored samples, there is no dif-
ference between the pre-mix and post-mix protocols in
AMH concentrations, as complement degradation has
already occurred resulting in minimal interference in the
assay [17].
Limits of high (>18 oocytes retrieved) and low (<6 oo-
cytes retrieved) ovarian response used in the current
analyses were selected as subjects with more than 18 oo-
cytes recovered have an increased risk of OHSS [3] and
those with fewer than six oocytes recovered have a com-
promised chance of pregnancy [1, 2]. These limits are
consistent with previous publications on excessive and
low ovarian response [7, 8].
In a retrospective analysis of a prospective randomized
trial in which patients aged 18–36 years were treated
with corifollitropin alfa or rFSH in a GnRH antagonist
protocol, the ongoing pregnancy success rates in high
responders (186 subjects with >18 oocytes) were at least
as high as in patients with fewer than 18 oocytes [18].
This difference from the Sunkara analysis [1] may be
related to the fact that these were women with a normalmenstrual cycle and body weight range, and those with
extremes in AFC and with polycystic ovary syndrome
were excluded. Also, the Sunkara analysis was mainly an
analysis of GnRH agonist cycles [1].
The current analyses of older women undergoing ovar-
ian stimulation with corifollitropin alfa in a GnRH an-
tagonist protocol uphold that age of the subject, AFC
and AMH are strong predictors of ovarian response, as
indicated in younger women undergoing ovarian stimula-
tion with rFSH in a GnRH agonist or antagonist protocol.
We conclude that in women aged 35 to 42 years
undergoing ovarian stimulation with corifollitropin alfa
in a GnRH antagonist protocol, AMH, AFC and age at
the start of stimulation were prognostic for both high
and low ovarian response, in addition to FSH for high
ovarian response and menstrual cycle length for low
ovarian response.
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